MARCADIA BIOTECH INC has a total of 14 patent applications. Its first patent ever was published in 2011. It filed its patents most often in China, Argentina and Australia. Its main competitors in its focus markets pharmaceuticals and biotechnology are KOSMAS KG, PEIXUE LING and WORLD TRADE IMP EXPORT WTIE A G.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 2 | |
#2 | Argentina | 1 | |
#3 | Australia | 1 | |
#4 | Brazil | 1 | |
#5 | Canada | 1 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | Republic of Korea | 1 | |
#8 | Mexico | 1 | |
#9 | New Zealand | 1 | |
#10 | Singapore | 1 | |
#11 | Taiwan | 1 | |
#12 | United States | 1 | |
#13 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Dimarchi Richard D | 13 |
#2 | Vignati Louis | 11 |
#3 | Zhang Lianshan | 2 |
#4 | Richard D Dimarchi | 1 |
#5 | Louis Vignati | 1 |
Publication | Filing date | Title |
---|---|---|
NZ611878A | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
TW201238972A | Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides |